The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE)

Journal of the Medical Association of Thailand

Volumn 91, Issue 10, 2008, Pages 1539-1543

  Leelawat, Kawin ^a   Laisupasin, Pikul ^b   Kiatdilokrut, Alongkorn ^b   Pongtongpool, Tavutchai ^a   Narong, Siriluk ^a   Samkhumphim, Nongluk ^a   Ket Horm, Sukit ^a  

^a RAJAVITHI HOSPITAL   (Thailand)

^b NATIONAL CANCER INSTITUTE   (Thailand)

Author keywords

Doxorubicin; Hepatocellular carcinoma; Mitomycin C; Transcatheter arterial chemoembolization; Vascular endothelial growth factor

Indexed keywords

DOXORUBICIN; MITOMYCIN C; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; SURVIVAL; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 55249097442     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Zhao JG, Feng GS, Kong XQ, Li X, Li MH, Cheng YS. Assessment of hepatocellular carcinoma vascularity before and after transcatheter arterial chemoembolization by using first pass perfusion weighted MR imaging. World J Gastroenterol 2004; 10: 1152-6.
2. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-21.
3. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 2008; 21: 1008-12.
4. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008; 11: 109-19.
5. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74: 191-201.
6. Jiang H, Fine JP. Survival analysis. Methods Mol Biol 2007; 404: 303-18.
7. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 2004; 10: 2878-82.
8. Poon RT, Lau C, Yu WC, Fan ST, Wong J. High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 2004; 11: 1077-84.
9. Xiong ZP, Yang SR, Xiao EH, Zhou SK, Zhang ZS, Liang ZY. Relation between vascular endothelial growth factor and reoccurence-metastasis after transcatheter arterial chemoembolization in hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2003; 25: 562-5.